RSS

Age-related macular degeneration (AMD)

The first patient in the UK has been successfully dosed with a novel gene therapy developed to treat age-related macular degeneration (AMD). Read more

News

The US Food and Drug Administration (FDA) has granted approval to Regeneron Pharmaceuticals for a supplemental biologics licence application (sBLA) for EYLEA (aflibercept) injection in patients with wet age-related macular degeneration (AMD). Read more

News

Bio-Rad Laboratories has launched a range of recombinant monoclonal anti-ranibizumab antibodies that are highly specific for the monoclonal antibody drug or the complex of the drug with its target, vascular endothelial growth factor A (VEGF-A). Read more

Technology

Genentech has unveiled positive results from its Phase II LADDER study, which evaluated the efficacy and safety of its investigational Port Delivery System with ranibizumab (PDS) in people with wet age-related macular degeneration (AMD). Read more

News

Scientists from the University of Birmingham have taken a further step in their research, developing an eye drop that could be a paradigm shift in the treatment arsenal for age-related macular degeneration (AMD). Read more

News

A co-development agreement has been formed by Xbrane Biopharma and STADA Arzeneimittel for the development of Xlucane — a biosimilar to Lucentis (ranibizumab), which is mainly used for the treatment of wet age-related macular degeneration (AMD). Read more

News

According to data and analytics company, GlobalData, pharmaceutical sales within the age-related macular degeneration (AMD) markets will soar to $11.5 billion by the year 2026. Read more

Analysis

The controversy surrounding Avastin and Lucentis has reared its head again as it has been revealed that health chiefs may face a legal fight if they go ahead with plans to offer the cheaper drug (Avastin) to patients with wet AMD on the NHS Read more

News

A type of eye drop has been developed by scientists at the University of Birmingham, UK, for the treatment of age-related macular degeneration (AMD), which is a leading cause of blindness. Read more

News